- Home
- ADPT
as 05-09-2025 4:00pm EST
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 1.1B | IPO Year: | 2019 |
| Target Price: | $9.83 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.99 - $10.28 | Next Earning Date: | 05-01-2025 |
| Revenue: | $189,527,000 | Revenue Growth: | 8.61% |
| Revenue Growth (this year): | 21.2% | Revenue Growth (next year): | 21.99% |
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | May 1 '25 | Sell | $7.35 | 68,412 | $502,828.20 | 1,279,524 | |
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Mar 24 '25 | Sell | $9.00 | 1,698 | $15,282.00 | 1,279,524 | |
| GRIFFIN MICHELLE RENEE | ADPT | Director | Mar 13 '25 | Sell | $7.19 | 36,291 | $260,932.29 | 15,394 | |
| HERSHBERG ROBERT | ADPT | Director | Mar 12 '25 | Sell | $7.59 | 53,000 | $402,270.00 | 69,690 | |
| NEUPERT PETER M | ADPT | Director | Mar 10 '25 | Sell | $7.05 | 10,000 | $70,500.00 | 224,690 | |
| GRIFFIN MICHELLE RENEE | ADPT | Director | Mar 4 '25 | Sell | $7.94 | 15,664 | $124,372.16 | 15,394 | |
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Mar 4 '25 | Sell | $6.99 | 96,656 | $675,219.41 | 1,279,524 | |
| PISKEL KYLE | ADPT | Chief Financial Officer | Mar 4 '25 | Sell | $6.98 | 10,320 | $72,072.21 | 276,227 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Mar 4 '25 | Sell | $7.20 | 219,569 | $1,600,416.95 | 2,814,350 | |
| BOBULSKY SUSAN | ADPT | Chief Commercial Officer, MRD | Mar 4 '25 | Sell | $6.98 | 26,023 | $181,640.54 | 347,238 |
Latest Adaptive Biotechnologies Corporation News
ADPT Breaking Stock News: Dive into ADPT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
Zacks
a day ago
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
MT Newswires
4 days ago
Adaptive Biotechnologies Insider Sold Shares Worth $502,828, According to a Recent SEC Filing
Simply Wall St.
5 days ago
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57
Simply Wall St.
6 days ago
Adaptive Biotechnologies First Quarter 2025 Earnings: Beats Expectations
MT Newswires
7 days ago
Sector Update: Health Care Stocks Higher Friday Afternoon
MT Newswires
7 days ago
Adaptive Biotechnologies Shares Surge After Q1 Loss Narrows, Revenue Rises
Thomson Reuters StreetEvents
7 days ago
Q1 2025 Adaptive Biotechnologies Corp Earnings Call
Compare ADPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.